Program to prevent lymphedema after breast cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study tests a comprehensive prevention program aimed at reducing the risk of lymphedema in women undergoing axillary lymph node dissection due to breast cancer. Participants will receive immediate lymphatic reconstruction, volumetric arm measurements, lymphatic massage, range of motion exercises, and compression garment use. The goal is to facilitate lymph fluid drainage and prevent the development of lymphedema. The study is designed for women aged 18 to 75 who have been diagnosed with breast cancer and consented to the surgical procedure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female sex
* Diagnosis of breast cancer
* Ages 18 to 75 years
* Consented for unilateral ALND or for unilateral SLNB with possible ALND

Exclusion Criteria:

* Male sex
* Does not speak English
* Does not fit into study garment
* Axillary recurrence
* History of ALND
* Requirement of bilateral ALND for the treatment of breast cancer
* Treatment with SLNB only
* Known anaphylactic allergy to ICG dye used in ILR
* Impaired decision-making capacity

Where it's running

• Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (Limited Protocol Activities)
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Commack (Limited Protocol Activities)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (Limited Protocol Activities)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Michelle Coriddi, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Michelle Coriddi, MD
• Email: coriddim@mskcc.org
• Phone: 646-608-8042

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Screening for Breast Cancer-Related Lymphedema in Targeted Therapy

  This study tests whether targeted breast cancer therapies are linked to lymphedema by tracking arm volume and symptoms in women undergoing treatment.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT05142800

• Upfront treatment for breast cancer with nodal metastases

  This study is testing if starting treatment with surgery and targeted therapy can help women with early-stage breast cancer that has spread to their lymph nodes live longer and have fewer recurrences.

  Recruiting at 3 sites Phase 2 Cedars-Sinai Medical Center · Los Angeles, California and 2 other locations · NCT06092892

• CSF sample collection from people with metastatic breast cancer to see brain metastasis risk

  This study tests whether spinal fluid and other samples can help predict brain metastases in adults with metastatic HER2-positive or triple-negative breast cancer who have not yet shown brain involvement.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619534

• Body composition and outcomes after breast reconstruction

  This study will see if detailed body composition measurements can help predict complications after mastectomy with immediate breast reconstruction in adult women.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07546331

• Support tool for women with HR+ breast cancer on long-term endocrine therapy

  This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07482384

• ENLIGHT algorithm to find treatment options for advanced metastatic breast cancer

  This test uses the ENLIGHT algorithm to try to find approved drugs that might work better for adults with triple-negative or endocrine therapy–resistant metastatic breast cancer.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07067138

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.